Opicapone (Ongentys®) is licensed as adjunctive therapy to levodopa and DOPA decarboxylase inhibitors (L-DOPA+DDCI) in adults with Parkinson’s disease and end-of-dose motor fluctuations in patients not stabilised on such combinations.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||14/12/2020|
|Rapid review completed||18/01/2021|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends opicapone not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.